Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
- Three Ella instruments commissioned at CLIA-certified Asuragen laboratory
- Inter-laboratory reproducibility studies underway between Melbourne and the US
- Clinical Validation expected to begin within the next month
- Approximately 1,470 samples across pivotal, specificity and healthy-individual studies
- FDA 510(k) submission remains targeted for H1 CY2027
US laboratory commissioned for final clinical testing phase
Cleo Diagnostics Limited (ASX:COV) has moved its pre-surgical ovarian cancer test closer to its final major clinical testing phase, commissioning three Ella automated immunoassay instruments at Asuragen, the CLIA-certified US laboratory operated by Bio-Techne (NASDAQ:TECH). Clinical Validation testing is expected to begin within the next month, once the test kits arrive.
The step gives Cleo a functioning US testing base, but it is not a clinical result or regulatory clearance. The company says the work will establish clinical performance data for the commercial assay in its intended-use population and support a planned FDA 510(k) submission in the first half of calendar 2027.
Reproducibility work links Melbourne and US laboratories
Before the main program begins, Cleo is conducting inter-laboratory reproducibility studies between its Melbourne facility and Asuragen. The studies will compare results generated at both sites using the same manufacturing batch, addressing whether the assay performs consistently across the two laboratory environments.
Asuragen's role had been announced in the company's US clinical validation appointment, which described the same approximately 1,470-sample program and its intended role in supporting the FDA submission. The current announcement marks operational progress on that plan, rather than a change to its stated regulatory objective.
Three studies will assess performance across 1,470 samples
The Clinical Validation program will draw on three populations. About 600 prospectively collected samples from Cleo's pivotal US trial across 19 sites will test the assay's ability to distinguish benign from malignant ovarian disease in women with a suspicious ovarian mass. A further 570 samples from people with non-ovarian benign and malignant conditions will assess potential confounding factors, while roughly 300 samples from healthy women will establish the expected score distribution without known disease.
Together, the studies are intended to generate measures including sensitivity and specificity within the test's intended clinical application. Cleo says those results, combined with its ongoing Analytical Validation program, will form the core evidence package for the 510(k) submission.
Analytical validation and data analysis remain ahead
The regulatory pathway still contains several substantive steps. Cleo must complete Analytical Validation across three independently manufactured production batches, finalise the commercial assay algorithm, complete Clinical Validation, analyse the clinical data and report the trial results before submitting to the FDA.
The company previously began formal Analytical Validation in a three-batch analytical program, but no validation results are disclosed in this announcement. The next meaningful evidence will therefore come from execution: reproducibility findings, the start and completion of the clinical studies, and the performance metrics generated from the defined sample groups.
Bottom Line?
Cleo has cleared an infrastructure milestone, but the investment case still depends on reproducibility, validation results and the FDA's response to the eventual 510(k) submission.
Questions in the middle?
- Will the inter-laboratory reproducibility studies identify any performance differences between Melbourne and Asuragen?
- Can Cleo complete Analytical and Clinical Validation, algorithm finalisation and data analysis within the H1 CY2027 submission target?
- What sensitivity and specificity will the 1,470-sample program produce in the intended pre-surgical population and control groups?